PDE inhibitors currently in early clinical trials for the treatment of asthma

Expert Opinion on Investigational Drugs

Volumn 23, Issue 9, 2014, Pages 1267-1275

  Matera, Maria Gabriella ^a   Page, Clive ^b   Cazzola, Mario ^c  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Asthma; PDE inhibitors; PDE isoforms; RPL554

Indexed keywords

BLX 028914; CHF 6001; GSK 256066; MEM 1414; PHOSPHODIESTERASE; PHOSPHODIESTERASE III; PHOSPHODIESTERASE III INHIBITOR; PHOSPHODIESTERASE INHIBITOR; PHOSPHODIESTERASE IV; PHOSPHODIESTERASE IV INHIBITOR; PHOSPHODIESTERASE V; PHOSPHODIESTERASE VII; REVAMILAST; RPL 554; UNCLASSIFIED DRUG; ANTIASTHMATIC AGENT; ANTIINFLAMMATORY AGENT; BRONCHODILATING AGENT;

ANTIINFLAMMATORY ACTIVITY; ASTHMA; DISEASE SEVERITY; DRUG EFFICACY; DRUG TREATMENT FAILURE; GASTROINTESTINAL SYMPTOM; HUMAN; NAUSEA; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PROTEIN FAMILY; REVIEW; UNSPECIFIED SIDE EFFECT; VOMITING; ANIMAL; CLINICAL TRIAL (TOPIC); DRUG DESIGN; PATHOPHYSIOLOGY;

ANIMALS; ANTI-ASTHMATIC AGENTS; ANTI-INFLAMMATORY AGENTS; ASTHMA; BRONCHODILATOR AGENTS; CLINICAL TRIALS AS TOPIC; DRUG DESIGN; HUMANS; PHOSPHODIESTERASE 3 INHIBITORS; PHOSPHODIESTERASE 4 INHIBITORS;

EID: 84906065026     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2014.921157     Document Type: Review

References (72)

1. Page CP, Spina D. Phosphodiesterase inhibitors in the treatment of inflammatory diseases. Handb Exp Pharmacol 2011;204:391-414
2. Chung KF. Phosphodiesterase inhibitors in airways disease. Eur J Pharmacol 2006;533:110-17
3. Rotella DP. Phosphodiesterases. In: Taylor JB, Triggle DJ, editors. Comprehensive medicinal chemistry II. Elsevier, Oxford, UK; 2007. p. 919-57
4. Page CP, Spina D, Selective PDE inhibitors as novel treatments for respiratory diseases. Curr Opin Pharmacol 2012;12:275-86
5. Jin SL, Goya S, Nakae S, et al. Phosphodiesterase 4B is essential for TH2-cell function and development of airway hyperresponsiveness in allergic asthma. J Allergy Clin Immunol 2010;126:1252-9.e12
6. Spina D. Phosphodiesterase-4 inhibitors in the treatment of inflammatory lung disease. Drugs 2003;63:2575-94
7. Spina D, Landells LJ, Page CP. The role of phosphodiesterase enzymes in allergy and asthma. Adv Pharmacol 1998;44:33-89
8. Yick CY, Zwinderman AH, Kunst PW, et al. Transcriptome sequencing (RNA-Seq) of human endobronchial biopsies: Asthma versus controls. Eur Respir J 2013;42:662-70
9. Houslay MD, Adams DR. PDE4 cAMP phosphodiesterase: Modular enzymes that orchestrate signalling cross-Talk, desensitization and compartmentalization. Biochem J 2003;370:1-18
10. Billington CK, Le Jeune IR, Young KW, Hall IP. A major functional role for phosphodiesterase 4D5 in human airway smooth muscle cells. Am J Respir Cell Mol Biol 2008;38:1-7
11. Trian T, Burgess JK, Niimi K, et al. Beta2-Agonist induced cAMP is decreased in asthmatic airway smooth muscle due to increased PDE4D. PLoS One 2011;6:e20000
12. Torphy TJ. Phosphodiesterase isoenzymes-molecular targets for novel anti-Asthma agents. Am J Respir Crit Care Med 1998;157:351-70
13. Smith SJ, Brookes-Fazakerley S, Donnelly LE, et al. Ubiquitous expression of phosphodiesterase 7A in human proinflammatory and immune cells. Am J Physiol Lung Cell Mol Physiol 2003;284:L279-89
14. Chevalier E, Lagente V, Dupont M, et al. Lack of involvement of type 7 phosphodiesterase in an experimental model of asthma. Eur Respir J 2012;39:582-8
15. Lugnier C. Cyclic nucleotide phosphodiesterase (PDE) superfamily: A new target for the development of specific therapeutic agents. Pharmacol Ther 2006;109:366-98
16. Shakur Y, Holst LS, Landstrom TR, et al. Regulation and function of the cyclic nucleotide phosphodiesterase (PDE3) gene family. Prog Nucleic Acid Res Mol Biol 2001;66:241-77
17. Reinhardt RR, Chin E, Zhou J, et al. Distinctive anatomical patterns of gene expression for cGMP-inhibited cyclic nucleotide phosphodiesterases. J Clin Invest 1995;95:1528-38
18. Maurice DH, Palmer D, Tilley DG, et al. Cyclic nucleotide phosphodiesterase activity, expression, and targeting in cells of the cardiovascular system. Mol Pharmacol 2003;64:533-46
19. Halpin DM. ABCD of the phosphodiesterase family: Interaction and differential activity in COPD. Int J Chron Obstruct Pulmon Dis 2008;3:543-61
20. Sebkhi A, Strange JW, Phillips SC, et al. Phosphodiesterase type 5 as a target for the treatment of hypoxia-induced pulmonary hypertension. Circulation 2003;107:3230-5
21. Barnett MS, Manning CD, Cieslinski LB, et al. The ability of phosphodiesterase IV inhibitors to suppress superoxide production in guinea pig eosinophils is correlated with inhibition of phosphodiesterase IV catalytic activity. J Pharmacol Exp Ther 1995;273:674-9
22. Santamaria LF, Palacios JM, Beleta J. Inhibition of eotaxin-mediated human eosinophil activation and migration by the selective cyclic nucleotide phosphodiesterase type 4 inhibitor rolipram. Br J Pharmacol 1997;121:1150-4
23. Giembycz MA. Phosphodiesterase 4 inhibitors and the treatment of asthma: Where are we now and where do we go from here? Drugs 2000;59:193-212
24. Jin SL, Richter W, Conti M. Insights into the physiological functions of PDE4 from knockout mice. In: Beavo JA, Francis SH, Houslay MD, editors. Cyclic nucleotide phosphodiesterases in health and disease. CRC Press, Boca Raton, USA; 2007. p. 323-46
25. Nieman RB, Fisher BD, Amit O, Dochorn RG. SB207499 (Ariflo), a second generation, selective oral phosphodiesterase type 4 (PDE4) inhibitor, attenuates exercise induced bronchoconstriction in patients with asthma (abstract). Am J Respir Crit Care Med 1998;157:A413
26. Compton C, Duggan M, Cedar E, et al. Ariflo efficacy in a 12 month study of patients with asthma (abstract). Am J Respir Crit Care Med 2000;161:A505
27. Timmer W, Leclerc V, Birraux G, et al. The new phosphodiesterase 4 inhibitor roflumilast is efficacious in exerciseinduced asthma and leads to suppression of LPS-stimulated TNF-Alpha ex vivo. J Clin Pharmacol 2002;42:297-303
28. Gauvreau GM, Boulet LP, Schmid-Wirlitsch C, et al. Roflumilast attenuates allergen-induced inflammation in mild asthmatic subjects. Respir Res 2011;12:140
29. Van Schalkwyk E, Strydom K, Williams Z, et al. Roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor, attenuates allergen-induced asthmatic reactions. J Allergy Clin Immunol 2005;116:292-8
30. Bateman ED, Izquierdo JL, Harnest U, et al. Efficacy and safety of roflumilast in the treatment of asthma. Ann Allergy Asthma Immunol 2006;96:679-86
31. Bousquet J, Aubier M, Sastre J, et al. Comparison of roflumilast, an oral anti-inflammatory, with beclomethasone dipropionate in the treatment of persistent asthma. Allergy 2006;61:72-8
32. Giembycz MA, Corrigan CJ, Seybold J, et al. Identification of cyclic AMP phosphodiesterases 3, 4 and 7 in human CD4+ and CD8+ T-lymphocytes: Role in regulating proliferation and the biosynthesis of interleukin-2. Br J Pharmacol 1996;118:1945-58
33. Fujimura M, Liu Q. Selective inhibitors for phosphodiesterase 3 and 4 in antigen-induced increase of cough reflex sensitivity in guinea pigs. Pulm Pharmacol Ther 2007;20:543-8
34. Bardin PG, Doward MA, Lampe FC, et al. Effect of selective phosphodiesterase 3 inhibition on the early and late asthmatic responses to inhaled allergen. Br J Clin Pharmacol 1998;45:387-91
35. Myou S, Fujimura M, Kamio Y, et al. Bronchodilator effects of intravenous olprinone, a phosphodiesterase 3 inhibitor, with and without aminophylline in asthmatic patients. Br J Clin Pharmacol 2003;55:341-6
36. Myou S, Fujimura M, Kamio Y, et al. Bronchodilator effect of inhaled olprinone, a phosphodiesterase 3 inhibitor, in asthmatic patients. Am J Respir Crit Care Med 1999;160:817-20
37. Jones NA, Leport M, Holand T, et al. Phosphodiesterase (PDE) 7 in inflammatory cells from patients with asthma and COPD. Pulm Pharmacol Ther 2007;20:60-8
38. Christensen I, Miskovicova H, Porvaznik I, et al. Selective inhibition of phosphodiesterase 7 (PDE7) by BRL50481 in healthy and ovalbumin-sensitized guinea pigs. Acta Medica Martiniana 2012;12(Suppl 1):16-23
39. Safavi M, Baeeri M, Abdollahi M. New methods for the discovery and synthesis of PDE7 inhibitors as new drugs for neurological and inflammatory disorders. Expert Opin Drug Discov 2013;8:733-51
40. Smith SJ, Cieslinski LB, Newton R, et al. Discovery of BRL. 50481 [3-(N, N-dimethylsulfonamido)-4-methylnitrobenzene], a selective inhibitor of phosphodiesterase 7: In vitro studies in human monocytes, lung macrophages, and CD8+ T-lymphocytes. Mol Pharmacol 2004;66:1679-89
41. Fortin M, DAnjou H, Higgins ME, et al. A multi-Target antisense approach against PDE4 and PDE7 reduces smoke-induced lung inflammation in mice. Respir Res 2009;10:39
42. Nijkamp FP, Folkerts G. Nitric oxide and bronchial hyperresponsiveness. Arch Int Pharmacodyn Ther 1995;329:81-96
43. Kapui Z, Schaeffer P, Mikus EG, et al. Experimental studies on guanosine 3,5-cyclic monophosphate levels and airway responsiveness of the novel phosphodiesterase type 5 inhibitor SR 265579 in guinea-pigs. Arzneimittelforschung 1999;49:685-93
44. Toward TJ, Smith N, Broadley KJ. Effect of phosphodiesterase-5 inhibitor, sildenafil (Viagra), in animal models of airways disease. Am J Respir Crit Care Med 2004;169:227-34
45. Wang T, Liu Y, Chen L, et al. Effect of sildenafil on acrolein-induced airway inflammation and mucus production in rats. Eur Respir J 2009;33:1122-32
46. Banner KH, Press NJ. Dual PDE3/4 inhibitors as therapeutic agents for chronic obstructive pulmonary disease. Br J Pharmacol 2009;157:892-906
47. Gerthoffer WT, Solway J, Camoretti-Mercado B. Emerging targets for novel therapy of asthma. Curr Opin Pharmacol 2013;13:324-30
48. Lu S, Liu N, Dass SB, et al. Randomized, placebo-controlled study of a selective PDE4 inhibitor in the treatment of asthma. Respir Med 2009;103:342-7
49. Gavaldà A, Roberts RS. Phosphodiesterase-4 inhibitors: A review of current developments (2010-2012). Expert Opin Ther Pat 2013;23:997-1016
50. Kobayashi M, Kubo S, Iwata M, et al. Anti-Asthmatic effect of ASP3258, a novel phosphodiesterase 4 inhibitor. Int Immunopharmacol 2011;11:732-9
51. Chapman RW, House A, Richard J, et al. Pharmacology of SCH900182, a potent, selective inhibitor of PDE4 for inhaled administration (Abstract). Am J Respir Crit Care Med 2010;181:A5671
52. Kwak HJ, Nam JY, Song JS, et al. Discovery of a novel orally active PDE-4 inhibitor effective in an ovalbumininduced asthma murine model. Eur J Pharmacol 2012;685:141-8
53. Yougbare I, Morin C, Senouvo FY, et al. NCS 613, a potent and specific PDE4 inhibitor, displays antiinflammatory effects on human lung tissues. Am J Physiol Lung Cell Mol Physiol 2011;301:L441-50
54. Anonymous Glenmark Pharmaceuticals (Q4 FY13). Available from: Http://m.indiainfoline.com/newsdetail/ResearchNews/Glenmark-Pharmaceuticals-Q4- FY13/42936817 [Last accessed 13 March 2014]
55. Leaker BR, Singh D, Barnes PJ, et al. The effect of the novel phosphodiesterase-4 inhibitor MEM 1414 on the allergen-induced responses in mild asthma (abstract). Am J Respir Crit Care Med 2010;181:A5613
56. Nials AT, Tralau-Stewart CJ, Gascoigne MH, et al. In vivo characterization of GSK256066, a high-Affinity inhaled phosphodiesterase 4 inhibitor. J Pharmacol Exp Ther 2011;337:137-44
57. Singh D, Petavy F, Macdonald AJ, et al. The inhaled phosphodiesterase 4 inhibitor GSK256066 reduces allergen challenge responses in asthma. Respir Res 2010;11:26
58. GlaxoSmithKline. Product development pipeline 2013. February 2013. Available from: Http://www.gsk.com/content/dam/gsk/globals/documents/pdf/GSK% 202013%20Pipeline.pdf [Last accessed 14 March 2014]
59. Anonymous Chiesi reports successful completion of Phase 2 proof of concept study. Available from: Http://www.drugs. com/clinical-trials/chiesi- reportssuccessful-completion-phase-2-proofconcept-study-16132.html [Last accessed 14 March 2014]
60. Page C, Cazzola M. Bifunctional drugs for the treatment of asthma and chronic obstructive pulmonary disease. Eur Respir J 2014. [Epub ahead of print]
61. Ochiai K, Takita S, Kojima A, et al. Phosphodiesterase inhibitors. Part 5: Hybrid PDE3/4 inhibitors as dual bronchorelaxant/anti-inflammatory agents for inhaled administration. Bioorg Med Chem Lett 2013;23:375-81
62. Packer M, Carver JR, Rodeheffer RJ, et al. Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. N Engl J Med 1991;325:1468-75
63. Ukena D, Rentz K, Reiber C, Sybrecht GW. Effects of the mixed phosphodiesterase III/IV inhibitor, zardaverine, on airway function in patients with chronic airflow obstruction. Respir Med 1995;89:441-4
64. Diamant Z, Spina D. PDE4-inhibitors: A novel, targeted therapy for obstructive airways disease. Pulm Pharmacol Ther 2011;24:353-60
65. Boswell-Smith V, Spina D, Oxford AW, et al. The pharmacology of two novel longacting phosphodiesterase 3/4 inhibitors, RPL554 [9,10-dimethoxy-2(2,4,6- Trimethylphenylimino)-3-(n-carbamoyl-2-Aminoethyl)-3,4,6, 7-Tetrahydro- 2Hpyrimido[ 6,1-A]isoquinolin-4-one] and RPL565 [6,7-dihydro-2-(2,6- diisopropylphenoxy)-9,10-dimethoxy-4Hpyrimido[6,1-A]isoquino lin-4-one].J Pharmacol Exp Ther 2006;318:840-8
66. Franciosi LG, Diamant Z, Banner KH, et al. Efficacy and safety of RPL554, a dual PDE3 and PDE4 inhibitor, in healthy volunteers and in patients with asthma or chronic obstructive pulmonary disease: Findings from four clinical trials. Lancet Respir Med 2013;1:714-27
67. Franciosi L, Diamant Z, Morelli N, et al. A combined phase I/IIa study of the safety, bronchodilator and bronchoprotective effects of nebulized RPL554, a dual PDE3/4-inhibitor, in healthy subjects and asthmatics (abstract). Clin Transl Allergy 2013;3(Suppl 1):O13
68. Spina D. PDE4 inhibitors: Current status. Br J Pharmacol 2008;155:308-15
69. Landells LJ, Szilagy CM, Jones NA, et al. Identification and quantification of phosphodiesterase 4 subtypes in CD4 and CD8 lymphocytes from healthy and asthmatic subjects. Br J Pharmacol 2001;133:722-9
70. Giembycz MA. Life after PDE4: Overcoming adverse events with dualspecificity phosphodiesterase inhibitors. Curr Opin Pharmacol 2005;5:238-44
71. Banner KH, Page CP. Dual PDE3/4 and PDE4 inhibitors: Novel treatments for COPD and other inflammatory airway diseases. Basic Clin Pharmacol Toxicol 2014;114(5):365-76
72. Green RH, Brightling CE, Woltmann G, et al. Analysis of induced sputum in adults with asthma: Identification of subgroup with isolated sputum neutrophilia and poor response to inhaled corticosteroids. Thorax 2002;57:875-9.